Table 2 Primary and key secondary endpoints in COMBO I and II

Percentage change in calculated LDL-C from baseline to week 24 in the ITT population, using all LDL-C values regardless of adherence to treatment (ITT analysis)

Key secondary endpoints

Percentage change in calculated LDL-C from baseline to week 24 in the modified ITT population, using all LDL-C values during the efficacy treatment period (on-treatment analysis)

Percentage change in calculated LDL-C from baseline to week 12 (ITT analysis)

Percentage change in calculated LDL-C from baseline to week 12 (on-treatment analysis)

Percentage change in Apo B from baseline to week 24 (ITT analysis)

Percentage change in Apo B from baseline to week 24 (on-treatment analysis)

Percentage change in non-HDL-C from baseline to week 24 (ITT analysis)

Percentage change in non-HDL-C from baseline to week 24 (on-treatment analysis)

Percentage change in total cholesterol from baseline to week 24 (ITT analysis)

Percentage change in Apo B from baseline to week 12 (ITT analysis)

Percentage change in non-HDL-C from baseline to week 12 (ITT analysis)

Percentage change in total cholesterol from baseline to week 12 (ITT analysis)

Percentage change in calculated LDL-C from baseline to week 52 (ITT analysis)

Proportion of patients reaching calculated LDL-C <70 mg/dL (1.81 mmol/L) at week 24 (ITT analysis)

Proportion of patients reaching calculated LDL-C <70 mg/dL (1.81 mmol/L) at week 24 (on-treatment analysis)

Percentage change in Lp(a) from baseline to week 24 (ITT analysis)

Percentage change in HDL-C from baseline to week 24 (ITT analysis)

Percentage change in fasting TGs from baseline to week 24 (ITT analysis)

Percentage change in Apo A1 from baseline to week 24 (ITT analysis)

Percentage change in Lp(a) from baseline to week 12 (ITT analysis)

Percentage change in HDL-C from baseline to week 12 (ITT analysis)

Percentage change in fasting TGs from baseline to week 12 (ITT analysis)

Percentage change in Apo A1 from baseline to week 12 (ITT analysis)